logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10316334 B1

PDFFull Text
Date of Patent:
Jun. 11, 2019

Filed:

Sep. 01, 2017

Cytomegalovirus vectors enabling control of t cell targeting

Applicant:

Oregon Health & Science University, Portland, OR (US);

Inventors:

Louis Picker, Portland, OR (US);

Scott Hansen, Portland, OR (US);

Klaus Frueh, Portland, OR (US);

Daniel Malouli, Hillsboro, OR (US);

Assignee:

Oregon Health & Science University, Portland, OR (US);

Attorney:

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Primary Examiner:

Rachel B Gill

Int. Cl.
CPC ...
C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 39/04 (2006.01); A61K 39/12 (2006.01); A61K 39/21 (2006.01); A61K 48/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 39/04 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); C12N 7/00 (2013.01); A61K 48/00 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/572 (2013.01); C12N 2710/16011 (2013.01); C12N 2710/16143 (2013.01); C12N 2740/15034 (2013.01);
Abstract

CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.

Find Patent Forward Citations

Picker, Louis. (2019). Cytomegalovirus vectors enabling control of t cell targeting (U.S. Patent No. 10316334). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10316334

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…